Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptSeeking Alpha • Monday
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling BuySeeking Alpha • Monday
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/12/26
Travere Is On A Crash Course With Its 200-Day Line — Here's What HappenedInvestors Business Daily • 11/03/26
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/02/26
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyBusiness Wire • 10/23/26
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineZacks Investment Research • 10/22/26
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Business Wire • 10/02/26
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPRNewsWire • 09/30/26
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental GlomerulosclerosisBusiness Wire • 09/23/26
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation ForumBusiness Wire • 09/17/26
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal PipelineMarketBeat • 08/18/26